 |
Hot Pursuit
13-Feb-23
|
|
|
|
|
|
|
|
|
|
|
|
Biocon says USFDA issues CRL for biologics license application for Bevacizumab
|
|
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Bevacizumab filed by partner Viatris (Mylan).
|
|
|
|
|
|
"The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan). The CRL informs the need for a satisfactory resolution of the observations made during the facility inspection conducted in August, 2022. We have submitted a comprehensive Corrective and Preventive Action (CAPA) plan, to the agency and are confident of addressing the observations within the stipulated timeframe. The CRL did not identify any outstanding scientific issues with the dossier," - Biocon Biologics spokesperson said.
Biocon is an innovation-led, global biopharmaceutical company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases.
The company had reported a net profit (before exceptional items) of Rs 168 crore in Q2 FY23, down by 10% from Rs 188 crore in Q2 FY22. Revenue from operations increased by 26% YoY to Rs 2,320 crore during the quarter.
The Biocon scrip fell 0.29% to settle trade at Rs 242.45 on Friday, 10 February 2023.
|
|
|
|
Previous News |
Biocon Ltd spurts 4.01%, rises for fifth straight session
(
Hot Pursuit
-
26-Apr-24
13:00
)
|
|
|
Biocon consolidated net profit declines 29.78% in the June 2023 quarter
(
Results
-
Announcements
11-Aug-23
07:47
)
|
|
|
Biocon Ltd spurts 0.58%, gains for fifth straight session
(
Hot Pursuit
-
04-Jan-24
13:00
)
|
|
|
Biocon reports consolidated net loss of Rs 41.80 crore in the December 2022 quarter
(
Results
-
Announcements
15-Feb-23
07:55
)
|
|
|
ICICI Bank board to mull fund raising proposal
(
Hot Pursuit
-
20-Apr-24
14:40
)
|
|
|
Biocon’s Andhra Pradesh facility gets 3 USFDA observations
(
Hot Pursuit
-
15-Jun-24
16:32
)
|
|
|
Biocon Ltd up for third straight session
(
Hot Pursuit
-
23-May-24
13:05
)
|
|
|
Biocon gains after subsidiary secures 'Yesafili' entry into Canadian market
(
Hot Pursuit
-
04-Mar-24
11:42
)
|
|
|
Biocon to conduct board meeting
(
Corporate News
-
22-Jul-23
10:58
)
|
|
|
Board of Biocon recommends final dividend
(
Corporate News
-
16-May-24
17:54
)
|
|
|
Biocon consolidated net profit rises 167.80% in the September 2023 quarter
(
Results
-
Announcements
10-Nov-23
17:28
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|